Nonalcoholic Fatty Liver Disease—A Novel Risk Factor for Recurrent Clostridioides difficile Infection

Šamadan, Lara; Jeličić, Mia; Vince, Adriana; Papić, Neven

Source / Izvornik: Antibiotics, 2021, 10

Journal article, Published version
Rad u časopisu, Objavljena verzija rada (izdavačev PDF)

https://doi.org/10.3390/antibiotics10070780

Permanent link / Trajna poveznica: https://urn.nsk.hr/urn:nbn:hr:105:748382

Rights / Prava: Attribution 4.0 International

Download date / Datum preuzimanja: 2022-06-21

Repository / Repozitorij:

Dr Med - University of Zagreb School of Medicine
Digital Repository
Nonalcoholic Fatty Liver Disease—A Novel Risk Factor for Recurrent *Clostridioides difficile* Infection

Lara Šamadan 1, Mia Jeličić 2, Adriana Vince 1,2 and Neven Papić 1,2,*

1 School of Medicine, University of Zagreb, 10000 Zagreb, Croatia; lsamadan@mef.hr (L.Š.); avince@bfm.hr (A.V.)
2 University Hospital for Infectious Diseases, 10000 Zagreb, Croatia; majdukovic@bfm.hr

Abstract: Recurrent *Clostridioides difficile* infections (rCDI) have a substantial impact on healthcare systems, with limited and often expensive therapeutic options. Nonalcoholic fatty liver disease (NAFLD) affects about 25% of the adult population and is associated with metabolic syndrome, changes in gut microbiome and bile acids biosynthesis, all possibly related with rCDI. The aim of this study was to determine whether NAFLD is a risk factor associated with rCDI. A retrospective cohort study included patients ≥60 years hospitalized with CDI. The cohort was divided into two groups: those who were and were not readmitted with CDI within 3 months of discharge. Of the 329 patients included, 107 patients (32.5%) experienced rCDI. Patients with rCDI were older, had higher Charlson Age–Comorbidity Index (CACI) and were more frequently hospitalized within 3 months. Except for chronic kidney disease and NAFLD, which were more frequent in the rCDI group, there were no differences in other comorbidities, antibiotic classes used and duration of antimicrobial therapy. Multivariable Cox regression analysis showed that age >75 years, NAFLD, CACI >6, chronic kidney disease, statins and immobility were associated with rCDI. In conclusion, our study identified NAFLD as a possible new host-related risk factor associated with rCDI.

Keywords: *Clostridioides difficile* associated disease; CDI; nonalcoholic fatty liver disease; NAFLD; NASH; recurrent disease

1. Introduction

*Clostridioides difficile* infection (CDI), with increasing prevalence and mortality rates, is the leading cause of healthcare-associated diarrhea [1]. On hospital admission, 7% of patients are already colonized with *C. difficile* and another 21% become infected during hospitalization [2]. Furthermore, 20 to 30% of patients will develop symptomatic CDI recurrence within 2 weeks of completion of accurate therapy, and each episode increases the risk of future episodes by about 20% [3,4]. Therefore, recurrent *C. difficile* infections (rCDI) cause substantial impact on healthcare systems with limited and often expensive therapeutic options [5]. This requires identification of patients at high risk of rCDI. So far, major risk factors suggested to be associated with rCDI were age, use of antibiotics for non-*C. difficile* infection, gastric acid suppression and infection with a hypervirulent strain (NAP1/BI/027) [5]. Age is the most frequently reported risk factor for rCDI; the probability of rCDI is 27% in the age group between 18 and 64 and 58.4% in patients older than 65 years [4,6]. However, the literature data on other host risk factors are inconsistent and often contradictory. Severe underlying comorbidities, chronic renal disease, CDI severity, prolonged hospital stay, and nursing home residency were inconsistently reported as additional risk factors [5–8]. Recently, it was suggested that metabolic syndrome and its components, primarily obesity and diabetes mellitus (DM), might be associated with rCDI [8,9]. Metabolic syndrome is linked with changes in gut microbiome that might serve as protective intestinal flora for *C. difficile* germination and disease development [10].
Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease, affecting about 25% of the adult Western population [11,12]. NAFLD represents a spectrum of chronic liver pathologies, from simple steatosis to nonalcoholic steatohepatitis, cirrhosis, and hepatocellular carcinoma [11,12]. There is a close relationship between NAFLD and metabolic syndrome, clustering visceral overweight, dyslipidemia, insulin resistance and arterial hypertension [11–13]. Some consider NAFLD as the hepatic manifestation of metabolic syndrome. Importantly, it is well described that changes in the gut microbiome promote the development of NAFLD through inflammatory processes, insulin resistance and bile acids metabolism, all possibly related with increased susceptibility to CDI [14,15]. We have recently shown that NAFLD is an independent risk factor for in-hospital CDI in elderly patients treated with systemic antimicrobial therapy [16]. Similarly, a case–control study showed that hospitalized patients with CDI more frequently have NAFLD and metabolic syndrome, as compared to age- and gender-matched controls hospitalized for non-CDI diarrhea [17]. However, the question remains if NAFLD is a risk factor for CDI recurrence. Due to the high and increasing burden of NAFLD in the Western population, identification of NAFLD as a novel and common risk factor could improve current CDI management strategies.

Therefore, the aim of this retrospective cohort study was to determine whether NAFLD is an independent risk factor associated with CDI recurrence in elderly patients who are at the highest risk for increased mortality, hospitalization, complications and healthcare costs.

2. Results

A total of 329 patients were included in the study (196, 59.6% females with the median age of 77, interquartile range (IQR) 71–83 years). Among the entire cohort, 107 (32.5%) patients developed recurrent CDI within 90 days of index hospitalization discharge or by the end of index CDI therapy (total of 171 episodes). Of those, 67 patients developed rCDI by 28 days (a cumulative probability of recurrence of 20.7%, 95% CI = 13.5–28.9%) and 40 patients by 90 days (33.3%, 26.5–40.4%). Three, four and five or more documented episodes were registered in the studied period in 38, 11 and 5 patients, respectively.

Patients with rCDI were older (78 years, IQR 74–84 vs. 77 years, 71–81), had higher Charlson Age–Comorbidity Index (CACI) (6, IQR 5–7 vs. 5, IQR 4–6) and were more frequently hospitalized within 3 months (81.3% vs. 68.9%). Except for chronic kidney disease (CKD) (26.2% vs. 6.8%) and NAFLD (34.6% vs. 18.5%), which were more frequent in the rCDI group, there were no differences in other comorbidities, as presented in Table 1. Notably, the majority of patients with CKD in our cohort did not undergo chronic dialysis; two patients in CDI and four in rCDI group were in a dialysis program.

High proportions of patients in both groups were nursing home residents (37.4% vs. 33.3%). Regarding chronic medications, patients without recurrence were more frequently receiving statins (23.4% vs. 13.1%), while there were no differences in prescription of peroral anti-diabetic, metformin or insulin. The majority of patients in both groups were receiving histamine-2 receptor antagonist and/or proton pump inhibitors (47.7% vs. 43.7%).

Use of specific of antibiotic classes per patient and duration of therapy prior the first episode of CDI were similar; fluoroquinolones were most frequently prescribed (29.9% vs. 27.0%), followed by 3rd generation cephalosporins (20.5% vs. 13.5%) and amoxicillin/clavulanate (19.6% vs. 22.1%). The reasons for antibiotic prescription prior the first episode of CDI were similar in both groups—most commonly for urinary tract infections (28.9% vs. 30.2%), respiratory infections (26.2% vs. 23.4%) and skin/soft tissue infections (11.2% vs. 5.9%). However, there were 9 patients with rCDI (8.4%) and 42 (18.9%) with CDI, for whom the reason for antibiotic prescription was not clear.

On index hospitalization, the majority of patients presented with severe CDI, median ATLAS score of 5 (IQR 4–7) in both groups, and elevated inflammatory markers (C-reactive protein and white blood cells count), as presented in Table 2. There were no differences in APRI or FIB4 scores between groups; APRI score >1.5 had 4.0% of patients in CDI and 2.8% in rCDI group. FIB4 score >3.25 had 10.8% in CDI and 10.3% of patients in rCDI group.
Table 1. Baseline patients’ characteristics.

| Characteristics                                      | Clostridioides difficile Infection (n = 222) | Recurrent Clostridioides difficile Infection (n = 107) | p-Value a |
|------------------------------------------------------|---------------------------------------------|-------------------------------------------------------|-----------|
| Age, median (IQR b)                                  | 77 (71–81)                                  | 78 (74–84)                                            | 0.011     |
| Female, No. (%)                                       | 135 (60.8%)                                 | 61 (57.0%)                                            | 0.549     |
| Nursing Home Resident                                 | 74 (33.3%)                                  | 40 (37.4%)                                            | 0.536     |
| Charlson Age–Comorbidity Index                       | 5 (4–6)                                     | 6 (5–7)                                               | <0.001    |
| Hospital Admission within 3 months                   | 153 (68.9%)                                 | 87 (81.3%)                                            | 0.018     |

Comorbidities

| Diabetes Mellitus                                     | 54 (24.3%)                                  | 34 (31.8%)                                            | 0.183     |
| Arterial Hypertension                                 | 108 (48.6%)                                 | 59 (55.1%)                                            | 0.291     |
| Cardiovascular Disease                                | 57 (25.7%)                                  | 18 (16.8%)                                            | 0.092     |
| Peripheral Vascular Disease                          | 20 (9.0%)                                   | 9 (8.4%)                                              | >0.999    |
| Hyperlipidemia                                        | 54 (24.3%)                                  | 25 (23.4%)                                            | 0.891     |
| Solid Tumor                                           | 22 (9.9%)                                   | 14 (13.1%)                                            | 0.451     |
| Chronic Kidney Disease                                | 15 (6.8%)                                   | 28 (26.2%)                                            | <0.001    |
| Chronic Obstructive Pulmonary Disease                 | 51 (22.9%)                                  | 19 (17.8%)                                            | 0.316     |
| Neurological Diseases                                 | 51 (22.9%)                                  | 27 (25.2%)                                            | 0.679     |
| Obesity (BMI > 30 kg/m²)                              | 23 (10.4%)                                  | 18 (16.8%)                                            | 0.109     |
| Body Mass Index (BMI) c                               | 25 (23–28)                                  | 27 (24–30)                                            | 0.010     |
| Nonalcoholic Fatty Liver Disease                     | 41 (18.5%)                                  | 37 (34.6%)                                            | 0.002     |

Use of Chronic Medications

| Statins                                              | 52 (23.4%)                                  | 14 (13.1%)                                            | 0.028     |
| Metformin                                            | 15 (6.8%)                                   | 13 (12.1%)                                            | 0.138     |
| Other Perioral Anti-diabetic                         | 13 (5.9%)                                   | 10 (9.3%)                                             | 0.255     |
| Insulin                                              | 22 (9.9%)                                   | 15 (14.0%)                                            | 0.269     |
| Histamine-2 Receptor Antagonist and/or Proton Pump Inhibitor | 97 (43.7%)                                  | 51 (47.7%)                                            | 0.554     |
| Immunosuppressive Agents                             | 20 (9.0%)                                   | 7 (6.5%)                                              | 0.525     |

Antibiotic Therapy before the 1st Episode of CDI

| Fluoroquinolones                                     | 60 (27.0%)                                  | 32 (29.9%)                                            | 0.510     |
| 1st Generation Cephalosporins                        | 1 (0.4%)                                    | 1 (0.9%)                                              | 0.545     |
| 2nd Generation Cephalosporins                        | 18 (8.1%)                                   | 7 (6.5%)                                              | 0.824     |
| 3rd Generation Cephalosporins                        | 30 (13.5%)                                  | 22 (20.5%)                                            | 0.108     |
| 4th Generation Cephalosporins                        | 3 (1.3%)                                    | 1 (0.9%)                                              | >0.999    |
| Amoxicillin/Clavulanate                              | 49 (22.1%)                                  | 21 (19.6%)                                            | 0.668     |
| Piperacillin/Tazobactam                               | 18 (8.1%)                                   | 9 (8.4%)                                              | >0.999    |
| Carbapenems                                          | 7 (3.1%)                                    | 5 (4.7%)                                              | 0.536     |
| Macrolides                                           | 22 (9.9%)                                   | 8 (7.5%)                                              | 0.544     |
| Clindamycin                                          | 12 (5.4%)                                   | 10 (9.3%)                                             | 0.237     |
| Others                                               | 6 (2.7%)                                    | 6 (5.6%)                                              | 0.214     |

a Fisher exact or Mann–Whitney U test, as appropriate; b IQR, interquartile range; c data available for 299 patients.

There was no difference in the choice of CDI treatment between groups; 118 patients were treated with metronidazole, 182 with vancomycin and 29 received combined therapy. There were 39 patients considered metronidazole unresponsive who were switched to vancomycin. Importantly, the majority of our cohort received non-CDI antibiotics during hospitalization (62.6% in rCDI and 67.6% in CDI group). As shown in Table 2, the most commonly used antibiotics were piperacillin/tazobactam (23.4% vs. 18.5%), 3rd generation cefuroxim (23.4% vs. 21.6%) and carbapenems (10.3% vs. 14.9%). The reasons for non-CDI therapy were respiratory tract infection (15.5%), urinary tract infection (30.7%), sepsis (7.9%) and suspected bacteraemia of gastrointestinal origin (6.1%). There were no differences between groups in the choice of antibiotic therapy, number of antibiotic classes prescribed or duration of antimicrobial therapy.
Table 2. Clinical, laboratory and treatment characteristics during the first episode of CDI.

| Characteristics                          | Clostridioides difficile Infection (n = 222) | Recurrent Clostridioides difficile Infection (n = 107) | p-Value a |
|-----------------------------------------|---------------------------------------------|-------------------------------------------------------|-----------|
| CDI Severity                            |                                             |                                                       |           |
| Nonsevere                               | 95 (42.8%)                                 | 45 (42.0%)                                            | 0.377     |
| Severe                                  | 100 (45.0%)                                | 54 (50.5%)                                            |           |
| Fulminant                                | 27 (12.2%)                                 | 8 (7.5%)                                              |           |
| ATLAS Score                             | 5 (4–7)                                    | 5 (4–7)                                               | 0.503     |
| Laboratory Findings on Admission        |                                             |                                                       |           |
| C-reactive Protein, mg/L                | 107.5 (54–172)                             | 94.1 (54.6–147.0)                                     | 0.294     |
| White Blood Cells Count, ×10⁹/L         | 14.5 (10.0–20.0)                           | 13.2 (10.1–19.6)                                      | 0.487     |
| Hemoglobin, g/L                         | 120 (107–129)                              | 120 (108–130)                                         | 0.851     |
| Platelets, ×10⁸                          | 251 (198–327)                              | 256 (190–327)                                         | 0.859     |
| Urea, mmol/L                            | 8.1 (5.3–13.0)                             | 7.1 (4.9–11.63)                                       | 0.256     |
| Creatinine, µmol/L                      | 103 (77.0–153.0)                           | 109 (75–145)                                          | 0.890     |
| Aspartate Aminotransferase, IU/L        | 19 (14–28)                                 | 19 (13–24)                                            | 0.146     |
| Alanine Aminotransferase, IU/L          | 15 (10–23)                                 | 14 (10–22)                                            | 0.581     |
| Serum Albumins, g/L                     | 27.8 (23.9–32.4)                           | 28.8 (24.8–33.9)                                      | 0.194     |
| CDI Treatment Regimen                   |                                             |                                                       |           |
| Metronidazole                           | 77 (34.7%)                                 | 41 (38.3%)                                            | 0.541     |
| Vancomycin                              | 122 (54.9%)                                | 60 (56.1%)                                            | 0.906     |
| Metronidazole + vancomycin              | 23 (10.4%)                                 | 6 (5.6%)                                              | 0.212     |
| Other Antimicrobials (not for C. difficile) |                                             |                                                       |           |
| Any Systemic Antibiotic                | 150 (67.6%)                                | 67 (62.6%)                                            | 0.387     |
| Fluoroquinolones                       | 9 (4.0%)                                   | 8 (7.5%)                                              | 0.194     |
| 1st Generation Cephalosporins          | 2 (0.9%)                                   | 0                                                      | >0.999    |
| 2nd Generation Cephalosporins          | 2 (0.9%)                                   | 1 (0.9%)                                              | >0.999    |
| 3rd Generation Cephalosporins          | 48 (21.6%)                                 | 25 (23.4%)                                            | 0.777     |
| 4th Generation Cephalosporins          | 2 (0.9%)                                   | 2 (1.9%)                                              | 0.598     |
| Amoxicillin Clavulanate                | 18 (8.1%)                                  | 8 (7.5%)                                              | >0.999    |
| Piperacillin/Tazobactam                | 41 (18.5%)                                 | 25 (23.4%)                                            | 0.307     |
| Carbapenems                             | 33 (14.9%)                                 | 11 (10.3%)                                            | 0.301     |
| Macrolides                              | 5 (2.2%)                                   | 5 (4.7%)                                              | 0.304     |
| Clindamycin                            | 1 (0.4%)                                   | 1 (0.9%)                                              | 0.545     |
| Others                                  | 8 (3.6%)                                   | 5 (4.7%)                                              | 0.763     |
| No. of Antibiotic Classes Used per Patient | 1 (0–3)                                 | 1 (0–3)                                               | 0.889     |

a Fisher exact or Mann–Whitney U test, as appropriate.

In order to identify potential risk factors for CDI recurrence, we performed a multivariable Cox regression analysis. After adjustment for potential cofounders, Charlson Age–Comorbidity Index >6 (Hazard ratio (HR) 1.97, 95% CI 1.32–2.92), age > 75 years (HR 1.88, 95% CI 1.20–2.97), NAFLD (HR 1.81, 95% CI 1.19–2.74, Figure 1), chronic kidney disease (HR 1.86, 95% CI 1.19–2.88) and immobility (HR 1.73, 95% CI 1.16–2.56) were associated with rCDI, as presented in Table 3. Chronic therapy with statins was associated with a decreased risk of rCDI (HR 0.24, 95% CI 0.11–0.52). Interestingly, some of the expected risk factors such as diabetes mellitus or obesity, nasogastric tube feeding and nursing home residency, as well as previous hospital admissions, choice of previous antibiotic therapy or concomitantly used antibiotics were not associated with rCDI in our model.

In addition, when NAFLD was combined with age > 75 years, chronic kidney disease and immobility, the risk of rCDI was even higher, as shown in Figure 2. Statin use was associated with lower rCDI in both patients with and without NAFLD (Figure 2, Panel d).
disease (HR 1.86, 95% CI 1.19–2.88) and immobility (HR 1.73, 95% CI 1.16–2.56) were associated with rCDI, as presented in Table 3. Chronic therapy with statins was associated with a decreased risk of rCDI (HR 0.24, 95% CI 0.11–0.52). Interestingly, some of the expected risk factors such as diabetes mellitus or obesity, nasogastric tube feeding and nursing home residency, as well as previous hospital admissions, choice of previous antibiotic therapy or concomitantly used antibiotics were not associated with rCDI in our model. In addition, when NAFLD was combined with age > 75 years, chronic kidney disease and immobility, the risk of rCDI was even higher, as shown in Figure 2. Statin use was associated with lower rCDI in both patients with and without NAFLD (Figure 2, Panel d).

Figure 1. Kaplan–Meier curves and Cox proportional hazard ratios (HR) for recurrence of *Clostridium difficile* infection in patients with and without nonalcoholic fatty liver disease.

Table 3. Multivariable Cox regression analysis of risk factors for the development recurrent *Clostridium difficile* infection.

| Variable                                | Hazard Ratio | 95% CI       | p-Value  |
|-----------------------------------------|--------------|--------------|----------|
| Age > 75 Years                          | 1.88         | 1.20 to 2.97 | 0.006    |
| Charlson Age–Comorbidity Index (CACI) > 6 | 1.97         | 1.32 to 2.92 | <0.001   |
| Immobility                             | 1.73         | 1.16 to 2.56 | 0.006    |
| Nonalcoholic Fatty Liver Disease       | 1.81         | 1.19 to 2.74 | 0.005    |
| Chronic Kidney Disease                 | 1.86         | 1.19 to 2.88 | 0.006    |
| Statins                                 | 0.24         | 0.11 to 0.52 | <0.001   |

The strength of association was expressed as hazard ratio (HR) and its corresponding 95% confidence interval (CI). The area under the ROC curve in the fully adjusted model was AUC 0.72 (95% CI 0.66 to 0.77).

Finally, we report the demographic and clinical characteristics of patients with NAFLD. As previously shown, they had significantly higher incidence of rCDI (47.4% vs. 27.9%). They were younger than patients without NAFLD (median of 76, IQR 71–81 vs. 78, IQR 72–83 years), more commonly had BMI > 30 (38.5% vs. 9.6%), diabetes mellitus (41.0% vs. 22.3%) and hyperlipidemia (33.3% vs. 21.1%) (data not shown). Consequently, they were more frequently prescribed statins (26.9% vs. 17.9%), metformin (11.5% vs. 7.9%) and insulin (17.9% vs. 9.2%) (data not shown). There was no difference in other comorbidities, chronic medications or antibiotics used. The 1st episode disease severity was similar to patients without NAFLD (ATLAS score of 5, IQR 4–6 vs. 6, IQR 4–7, p = 0.103) (data not shown).
Sixty-eight patients (18.9%) had NAFLD (mean age 65 years, IQR 72–83 years), more commonly had BMI > 30 (38.5% vs. 9.6%), diabetes mellitus (41.0% vs. 22.3%) and hyperlipidemia (33.3% vs. 21.1%) (data not shown). Consequently, they were more frequently prescribed statins (26.9% vs. 17.9%), metformin (11.5% vs. 7.9%) and insulin (17.9% vs. 9.2%) (data not shown). There was no difference in other comorbidities, chronic medications or antibiotics used. The 1st episode disease severity was similar to patients without NAFLD (ATL AS score of 5, IQR 4–6 vs. 6, IQR 4–7, p = 0.103) (data not shown).

Figure 2. Kaplan–Meier curves for recurrence of *Clostridioides difficile* infection (CDI). Using the Kaplan–Meier method, a proportion of patients with CDI recurrence stratified by the concomitant presence of NAFLD and (a) age, (b) chronic kidney disease, (c) immobility and (d) statins during the follow-up period.

3. Discussion

Over the last decade, there has been a marked increase in the incidence and severity of CDI, with relapsing episodes now occurring at a higher frequency, especially in the elderly. Notably, recurrent CDI is associated with a significantly higher risk of death within six months after initial CDI treatment completion, compared with CDI patients who do not develop a recurrence [18,19].

In this retrospective cohort study, we found a significant association between recurrent CDI and NAFLD in elderly patients. Moreover, this appears to be independent of a number of potential confounders, specifically other components of metabolic syndrome.

While there are several well-established risk factors for primary infection with *C. difficile*, the studies examining risk factors for CDI recurrence had variable results depending on the population studied. To the best of our knowledge, none of them have analyzed the impact of NAFLD on CDI recurrence.

Surprisingly, the investigation of the role of NAFLD in bacterial infections has only recently been initiated. Although patients with NAFLD might have a higher risk for infections due to the concomitant presence of obesity or diabetes mellitus, few studies that included NAFLD in the analysis consistently showed its outcome impact independently of the metabolic syndrome components [20]. So far, this was suggested for community-acquired pneumonia, bacteraemia of gastrointestinal origin, sepsis and urinary tract infections [21–25]. Recently, we have shown that NAFLD is a risk factor for in-hospital CDI development in elderly patients treated with systemic antimicrobial therapy [16].

The possible explanation of increased risk of CDI in NAFLD patients includes changes in intestinal microbiota linked to the development and progression of NAFLD [13]. While *Bacteroides* and *Bifidobacterium* play an important role in the mechanism, preventing colonization by *C. difficile*, patients with NAFLD were shown to have a relative decrease in
the proportion of *Bacteroides* to *Firmicutes* [13,26,27]. Notably, NAFLD is now considered a multisystem disease due to the persistent low-level inflammation with impaired immune response that might predispose patients to a variety of infections [13,28].

In our cohort, DM and obesity were not associated with rCDI. The current medical literature is contradictory on the association between obesity and *C. difficile* infection. Two case–control studies that examined the association of CDI with BMI showed different results. While Bishara et al., based on data collected from 148 adult patients with CDI, showed an association of BMI with CDI (OR = 1.196 per 1-unit increase in BMI scale) [9], Punni et al. in their study on 189 patients did not [29]. There was no association of obesity with the risk of *C. difficile* infection among patients with ulcerative colitis and according to another study, obesity was even associated with decreased risk of CDI in hospitalized patients with pouchitis [30,31].

Meanwhile, several studies have shown that DM increases the risk of CDI recurrence, but none of them included NAFLD as a variable. A large Spanish cohort study showed a significantly higher incidence of CDI in DM patients, with an increasing trend between 2011 and 2015 [32]. In addition, patients with DM have significantly higher probability for hospital readmission due to CDI (adjusted OR of 3.79 to 5.46) and the development of severe CDI [8,33]. DM was also recognized as an independent risk factor in patients with toxigenic *C. difficile* colonization to develop *C. difficile*-associated diarrhea [7].

Interestingly, it was shown that metformin increases the *Bacteroidetes*/*Firmicutes* ratio; therefore, it may yield a protective effect against CDI in patients with DM [34]. A retrospective, case–control study compared CDI diabetic patients to diabetic patients without CDI and found metformin treatment to be associated with significant reduction in CDI (OR 0.58) [35]. This could be partially explained by the study that showed that metformin reduces vegetative cell growth of *C. difficile* in vitro, as well as ex vivo in human microbiome culture system [36]. Metformin modified human gut microbiome by decreasing *C. difficile* growth while increasing the growth of non-pathogenic *Clostridium* strains [36].

Other risk factors for rCDI in our study were age, significant comorbidities measured with Charlson Age–Comorbidity Index (CACI), chronic kidney disease and immobility.

Several studies examined the association of CKD with CDI. While the association of severe CKD requiring dialysis with CDI severity and mortality is clear, there are inconsistent data on if patients not undergoing dialysis are at higher risk for CDI [37–40]. We provide additional data that patients with CKD not requiring chronic dialysis are at increased risk for rCDI.

Meanwhile, antibiotics and proton pump inhibitors, which are well-known risk factors for initial CDI and rCDI, were not associated with rCDI in our study. This might be due to the characteristics of our cohort and widespread use of these medications, which might have predisposed the development of CDI in the first place.

Next, we found that statin use was associated with lower rCDI in patients both with and without NAFLD. Due to the global epidemic of cardiovascular diseases, obesity and metabolic syndrome, statins are considered as one of the most commonly used medications worldwide [41]. Other than their cholesterol-lowering effect, they also have an anti-inflammatory and immunomodulatory properties [42]. According to a recent meta-analysis of available data, the risk of developing CDI was approximately 25% lower in statin users compared with non-users [43]. However, this meta-analysis included eight observational studies with significant heterogeneity. There are no randomized control trials published so far. Although the exact mechanisms of risk decrease in CDI in statin users remains unknown, some studies demonstrated that statins have an influence on gut microbiota and could change its composition [44–46]. Vieira-Silva et al. recently identified statins as a key covariate of gut microbiome diversification [45]. In their study examining obesity-associated microbiota alterations, they showed that obesity is linked with intestinal microbiota configuration characterized by a high proportion of *Bacteroides*, a low proportion of *Faecalibacterium* and low microbial cell densities (the so called Bact2 enterotype) [45]. However, patients treated with statins had significantly lower Bact2 prevalence [45]. A
systematic review of both human and animal data showed that statins modulate the gut microbiome, but the effect of change is unclear, probably due to the differences in populations studied [46]. It seems reasonable to speculate that modulation of the gut microbiome by statins might aid in the restoration of colonization resistance and lower recurrence of CDI. Alternatively, as statins have anti-inflammatory properties, their use may decrease the inflammatory response to *C. difficile* infection, which may lead to the decreased severity of CDI [47].

The major limitation of this study comes from its retrospective, monocentric design, and despite adjustment for a variety of demographics, comorbidities and medications, residual confounding may exist. The diagnosis of NAFLD was based on abdominal US, which is operator-dependent, and patients were not systematically screened for other causes of liver steatosis, but from data available in medical charts. Importantly, US has limited sensitivity and does not reliably detect steatosis when <20% or in individuals with high body mass index (BMI) (>40 kg/m²) and is inferior to MRI or CT scan for detection and grading of steatosis [48,49]. Next, while any potential effects of NAFLD should be interpreted in connection with metabolic syndrome, due to the retrospective design, we could not include waist circumference, type of dyslipidemia, levels of triglycerides or HDL cholesterol. However, we included diabetes mellitus and obesity (defined by BMI > 30 kg/m²), which might have the highest confounding impact, and have both been previously shown to be associated with rCDI. Since only a minority of patients had a significant risk of advanced fibrosis, as measured by APRI and FIB4 score, we were not able to determine the effect of advanced NAFLD on rCDI. Another limitation was the lack of data on *C. difficile* strain, which might be important since 027/BI/NAP1 strain has been associated with increased risk of CDI recurrence [50]. The study was designed to investigate the effect of NAFLD in elderly who are at the highest risk for rCDI and included only patients who were rehospitalized during a 3-month period. Therefore, patients diagnosed and treated for rCDI entirely as outpatients would not have been identified as having a recurrence. However, this would underestimate, rather than overestimate, the impact of NAFLD on patient outcomes.

Nevertheless, we report the first data examining the association of NAFLD with rCDI.

4. Materials and Methods

4.1. Study Design and Patients

This was a retrospective cohort study conducted at the University Hospital for Infectious Diseases Zagreb (UHID), Croatia, which is a national referral center for infectious diseases. We reviewed the hospital records of all adult patients hospitalized at UHID with a diagnosis of *Clostridium difficile* infection over a 5-year period (2016–2019). We included patients > 60 years diagnosed with the first episode of CDI. Patients who had a previous episode of CDI within three months before index hospitalization were excluded, as well as patients with known alcohol abuse and/or those diagnosed with chronic viral hepatitis or with a history of other known liver diseases. Next, only patients with performed ultrasonography examination to assess liver steatosis were included in study. During the period studied, a total of 841 patients were hospitalized with diagnosis of CDI. Of those, 730 were >60 years (total of 999 episodes of CDI). A total of 401 patients were excluded: 31 had CDI within 3 months, significant alcohol intake in 38, chronic viral hepatitis in 21, cirrhosis in 11 and hepatotoxic medications in 14 patients. There were 267 patients who did not have abdominal imaging, and 19 patients died during initial hospitalization. In the end, 329 patients were included in the study. The cohort was divided into two groups, those who were and were not readmitted with CDI within 3 months of discharge, as described in a flowchart (Figure 3).
4.2. Data Collection, Outcomes, and Definitions

We collected multiple variables that could be associated with patient outcomes. These variables included demographic data (age, sex and residence in nursing homes) and medical history (comorbidities (measured by Charlson Age–Comorbidity Index, CACI [51]), chronic medications, hospital admission within 3 months, administration of antibiotics within 90 days). CDI was defined as the presence of 3 or more unformed stools in 24 or fewer consecutive hours, confirmed with positive two-stage *C. difficile* stool tests (screening GDH test confirmed with toxin A/B PCR), according to current guidelines [52–54]. CDI severity was determined by ATLAS score calculation [55]. CDI treatment regimen, its duration and the use of other non-CDI antimicrobials were collected. Selected blood laboratory data at the admission were analyzed: C-reactive protein level, white blood cell count, platelet count, hemoglobin, blood urea nitrogen, serum creatinine, aspartate aminotransferase, alanine aminotransferase, gamma-glutamyl transferase, alkaline phosphatase, bilirubin and serum albumin concentration. In addition, as a surrogate marker of liver injury, APRI and FIB-4 score were calculated for all patients [56]. Using the CKD-EPI equation, we calculated estimated glomerular filtration rate (eGFR) [57]. The diagnosis of NAFLD was made based on the results of abdominal ultrasound and by the absence of a secondary cause of NAFLD, according to current guidelines [11,12]. The liver steatosis was assessed by ultrasound in all patients by an experienced radiologist, and defined as finding liver parenchyma with increased echogenicity and sound attenuation [49].

The primary study outcome was rCDI, defined as CDI occurring within 14–90 days of the initial CDI diagnosis date. Same as CDI, rCDI was defined based on compatible symptoms accompanied by a positive laboratory test.

---

Figure 3. Study design flow chart.
4.3. Statistical Analysis

The clinical characteristics, laboratory and demographic data were evaluated and descriptively presented. We used Fisher’s exact test and the Mann–Whitney U test to compare the groups. All tests were two-tailed; a $p$ value < 0.05 was considered statistically significant. Time to CDI recurrence was evaluated using the Kaplan–Meier method, and the comparison of CDI recurrence risk between patients with and without NAFLD was made using the log-rank test. Risk factors for the development of the rCDI were investigated using a univariate, and subsequently, a multivariable Cox regression model by estimating the hazard ratio (HR) and its 95% CI for the time from cure date of the primary CDI to the first episode of rCDI. Variables with $p < 0.2$ on univariate analysis or with clinical/biological plausibility were included in initial multivariable models. Multivariable Cox proportional hazards models were developed using backward elimination with $p < 0.1$ to retain variables in the model. Statistical analyses were performed using the GraphPad Prism Software version 9.1.1. (San Diego, CA, USA) and MedCalc version 20.008 (MedCalc Software, Ostend, Belgium).

5. Conclusions

In conclusion, we have shown that NAFLD is a novel host-related risk factor for recurrent CDI in elderly patients. This might be relevant for several reasons. Firstly, this highlights the need to include NAFLD as a variable in future studies, examining both CDI and rCDI. Secondly, patients with NAFLD might benefit from screening strategies, preemptive treatment or prophylactic measures, such as antibiotic prophylaxis that has recently been investigated [58,59]. The finding that statins reduce the risk of rCDI in both patients with and without NAFLD might be a novel treatment option that warrants further examination. Finally, there is growing evidence that immunological changes in patients with NAFLD might have a profound impact in the course of bacterial infections, the place where we have not been looking so far.

Author Contributions: Conceptualization, N.P. and A.V.; methodology, N.P.; validation, A.V.; resources, N.P.; data curation, L.Š., M.J.; writing—original draft preparation, L.Š., M.J.; writing—review and editing, N.P., A.V.; supervision, A.V.; funding acquisition, N.P. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by the Croatian Science Foundation, for the project entitled “The role of immune semaphorins in NAFLD and sepsis” (principal investigator Neven Papić, project number UIP-2019–04–7194).

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Institutional Review Board (or Ethics Committee) of the University Hospital for Infectious Diseases Zagreb (protocol code 01–1247–2–2019, date of approval 30 August 2019).

Informed Consent Statement: Patient consent was waived due to retrospective design of the study.

Data Availability Statement: The datasets generated and/or analyzed during the current study are available from the corresponding author on reasonable request.

Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

References
1. Magill, S.S.; Edwards, J.R.; Bamberg, W.; Beldavs, Z.G.; Dumyati, G.; Kainer, M.A.; Lynfield, R.; Maloney, M.; McAllister-Hollo, L.; Nadle, J.; et al. Multistate point-prevalence survey of health care-associated infections. N. Engl. J. Med. 2014, 370, 1198–1208. [CrossRef]
2. Crobach, M.J.T.; Vernon, J.J.; Loo, V.G.; Kong, L.Y.; Pechine, S.; Wilcox, M.H.; Kuipper, E.J. Understanding Clostridium difficile Colonization. Clin. Microbiol. Rev. 2018, 31. [CrossRef] [PubMed]
3. Louie, T.J.; Miller, M.A.; Mullane, K.M.; Weiss, K.; Lentnek, A.; Golan, Y.; Gorbach, S.; Sears, P.; Shue, Y.K.; Group, O.P.T.C.S. Fidaxomicin versus vancomycin for Clostridium difficile infection. N. Engl. J. Med. 2011, 364, 422–431. [CrossRef] [PubMed]
4. Pepin, J.; Alary, M.E.; Valiquette, L.; Raiche, E.; Ruel, J.; Fulop, K.; Godin, D.; Bourassa, C. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin. Infect. Dis. 2005, 40, 1591–1597. [CrossRef] [PubMed]

5. Song, J.H.; Kim, Y.S. Recurrent Clostridium difficile Infection: Risk Factors, Treatment, and Prevention. Gut Liver 2019, 13, 16–24. [CrossRef] [PubMed]

6. Deshpande, A.; Pasupuleti, V.; Thota, P.; Pant, C.; Rolston, D.D.; Hernandez, A.V.; Donskey, C.J.; Fraser, T.G. Risk factors for recurrent Clostridium difficile infection: A systematic review and meta-analysis. Infect. Control Hosp. Epidemiol. 2015, 36, 452–460. [CrossRef]

7. Lin, H.J.; Hung, Y.P.; Liu, H.C.; Lee, J.C.; Lee, C.I.; Wu, Y.H.; Tsai, P.J.; Ko, W.C. Risk factors for Clostridium difficile-associated diarrhea among hospitalized adults with fecal toxicogenic C. difficile colonization. J. Microbiol. Immunol. Infect. 2015, 48, 183–189. [CrossRef]

8. Shakov, R.; Salazar, R.S.; Kagunye, S.K.; Baddoura, W.J.; DeBarri, V.A. Diabetes mellitus as a risk factor for recurrence of Clostridium difficile infection in the acute care hospital setting. Am. J. Infect. Control 2011, 39, 194–198. [CrossRef]

9. Bishara, J.; Farah, R.; Mograbi, J.; Khalaila, W.; Abu-Elheja, O.; Mahamid, M.; Nseir, W. Obesity as a risk factor for Clostridium difficile infection. Clin. Infect. Dis. 2013, 57, 489–493. [CrossRef]

10. Czepiel, J.; Drozdz, M.; Pituch, H.; Kuiper, E.J.; Perucki, W.; Mielimonka, A.; Goldman, S.; Wultanska, D.; Garlicki, A.; Biesiada, G. Clostridium difficile infection: Review. Eur. J. Clin. Microbiol. Infect. Dis. 2019, 38, 1211–1221. [CrossRef]

11. European Association for the Study of The Liver; European Association for the Study of Diabetes; European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J. Hepatol. 2016, 64, 1388–1402. [CrossRef] [PubMed]

12. Chalasani, N.; Younossi, Z.; Lavine, J.E.; Charlton, M.; Cusi, K.; Rinella, M.; Harrison, S.A.; Brunt, E.M.; Sanyal, A.J. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018, 67, 328–357. [CrossRef]

13. Haas, J.T.; Francque, S.; Staels, B. Pathophysiology and Mechanisms of Nonalcoholic Fatty Liver Disease. Ann. Rev. Physiol. 2016, 78, 181–205. [CrossRef]

14. Jayakumar, S.; Loomba, R. Review article: Emerging role of the gut microbiome in the progression of nonalcoholic fatty liver disease and potential therapeutic implications. Aliment. Pharmacol. Ther. 2019, 50, 144–158. [CrossRef] [PubMed]

15. Hopkins, M.J.; Macfarlane, G.T. Changes in predominant bacterial populations in human faeces with age and with Clostridium difficile infection. J. Med. Microbiol. 2002, 51, 448–454. [CrossRef]

16. Papic, N.; Jelovcic, F.; Karlovic, M.; Maric, L.S.; Vince, A. Nonalcoholic fatty liver disease as a risk factor for Clostridiodioides difficile infection. Eur. J. Clin. Microbiol. Infect. Dis. 2020, 39, 569–574. [CrossRef]

17. Nseir, W.B.; Hussein, S.H.H.; Farah, R.; Mahamid, M.N.; Khatif, H.H.; Mograbi, J.M.; Peretz, A.; Amara, A.E. Nonalcoholic fatty liver disease as a risk factor for Clostridium difficile-associated diarrhea. J. Hepatol. 2016, 64, 1388–1402. [CrossRef] [PubMed]

18. Olsen, M.A.; Yan, Y.; Reske, K.A.; Zilberberg, M.D.; Dubberke, E.R. Recurrent Clostridium difficile infection is associated with increased mortality. Clin. Microbiol. Infect. 2015, 21, 164–170. [CrossRef]

19. Cozar, A.; Ramos-Martinez, A.; Merino, E.; Martinez-Garcia, C.; Shaw, E.; Marrodan, T.; Calbo, E.; Bereciartua, E.; Sanchez-Munoz, L.A.; Salavert, M.; et al. High delayed mortality after the first episode of Clostridium difficile infection. Anaerobe 2019, 57, 93–98. [CrossRef]

20. Adenote, A.; Dumic, I.; Madrid, C.; Barusya, C.; Nordstrom, C.W.; Rueda Prada, L. NAFLD and Infection, a Nuanced Relationship. Gut Liver 2020, 14, 806–824. [CrossRef]

21. Flaherty, A.; Sanna, M.; Carter, A.; et al. Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease. Cell Metab. 2019, 30, 607. [CrossRef] [PubMed]

22. Van Hecke, M.A.; Weyler, J.; Kwanten, W.J.; Dirinck, E.L.; De Winter, B.Y.; Francque, S.M.; Vonghia, L. The Differential Roles of T Cells in Non-alcoholic Fatty Liver Disease and Obesity. Front. Immunol. 2019, 10, 82. [CrossRef]

23. Parnell, E.; Pula, J.L.; Asslo, F.; Baddoura, W.; DeBarri, V.A. Is obesity a risk factor for Clostridium difficile infection? Obes. Res. Clin. Pract. 2015, 9, 50–54. [CrossRef]
30. Chandradas, S.; Khalili, H.; Ananthakrishnan, A.; Wayman, C.; Reidel, W.; Waalen, J.; Konijeti, G.G. Does Obesity Influence the Risk of Clostridium difficile Infection Among Patients with Ulcerative Colitis? Dig. Dis. Sci. 2018, 63, 2445-2450. [CrossRef]
31. Gosal, F.; Covut, F.; Alomari, M.; Hitawala, A.; Singh, A.; Kisangani, G.; Lopez, R.; Shen, B. Obesity Is Associated with Decreased Risk of Clostridium difficile Infection in Hospitalized Patients with Pouchitis. Dig. Dis. Sci. 2020, 65, 1422–1428. [CrossRef]
32. Lopez-de-Andres, A.; Esteban-Vasallo, M.D.; de Miguel-Diez, J.; Hernandez-Barrera, V.; de Miguel-Yanes, J.M.; Mendez-Bailon, M.; Jimenez-Garcia, R. Incidence and in-hospital outcomes of Clostridium difficile infection among type 2 diabetes patients in Spain. Int. J. Clin. Pract. 2018, 72, e13251. [CrossRef] [PubMed]
33. Wernisch, J.M.; Schmid, D.; Kuo, H.W.; Simons, E.; Allerberger, F.; Michl, V.; Tesik, P.; Tucek, G.; Wernisch, C. Hospital-acquired Clostridium difficile infection: Determinants for severe disease. Eur. J. Clin. Microbiol. Infect. Dis. 2012, 31, 1923–1930. [CrossRef]
34. Karlsson, F.H.; Tremaroli, V.; Nookaew, I.; Bergstrom, G.; Behre, C.J.; Fagerberg, B.; Nielsen, J.; Backhed, F. Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature 2013, 498, 99–103. [CrossRef] [PubMed]
35. Eliaikim-Raz, N.; Fishman, G.; Yahav, D.; Goldberg, E.; Stein, G.Y.; Zvi, H.B.; Barsheshet, A.; Bishara, J. Predicting Clostridium difficile infection in diabetic patients and the effect of metformin therapy: A retrospective, case-control study. Eur. J. Clin. Microbiol. Infect. Dis. 2015, 34, 1201–1205. [CrossRef] [PubMed]
36. Wang, S.; Yadav, H. Metformin reduces Clostridium difficile infection. FASEB J. 2021, 35. [CrossRef]
37. Eddi, R.; Malik, M.N.; Shakov, R.; Baddoura, W.J.; Chandran, C.; Debari, V.A. Chronic kidney disease as a risk factor for Clostridium difficile infection. Nephrology 2010, 15, 471–475. [CrossRef]
38. Yousuf, K.; Saklayen, M.G.; Markert, R.J.; Barde, C.J.; Gopalswamy, N. Clostridium difficile-associated diarrhea and chronic renal insufficiency. South. Med. J. 2002, 95, 681–683. [PubMed]
39. Kim, S.C.; Seo, M.Y.; Lee, J.Y.; Kim, K.T.; Cho, E.; Kim, M.G.; Jo, S.K.; Cho, W.Y.; Kim, H.K. Advanced chronic kidney disease: A strong risk factor for Clostridium difficile infection. Korean J. Intern. Med. 2016, 31, 125–133. [CrossRef]
40. Keddis, M.T.; Khanna, S.; Noheria, A.; Baddour, L.M.; Pardi, D.S.; Qian, Q. Clostridium difficile infection in patients with chronic kidney disease. Mayo Clin. Proc. 2012, 87, 1046–1053. [CrossRef]
41. Adedinsewo, D.; Taka, N.; Agasthi, P.; Sachdeva, R.; Rust, G.; Onwuanyi, A. Prevalence and Factors Associated With Statin Use Among a Nationally Representative Sample of US Adults: National Health and Nutrition Examination Survey, 2011–2012. Clin. Cardiol. 2016, 39, 491–496. [CrossRef] [PubMed]
42. Ferri, N.; Corsini, A.; Bellosta, S. Pharmacology of the new P2Y12 receptor inhibitors: Insights on pharmacokinetic and pharmacodynamic properties. Drugs 2013, 73, 1681–1709. [CrossRef] [PubMed]
43. Wijarnpreecha, K.; Panjawatanan, P.; Thongprayoon, C.; Ungprasert, P. Statins & risk of Clostridium difficile infection: A meta-analysis. Indian J. Med. Res. 2019, 150, 359–364. [CrossRef] [PubMed]
44. Nolan, J.A.; Skuse, P.; Govindarajan, K.; Patterson, E.; Konstantinidou, K.; Patterson, E.; MacSharry, J.; Shanahan, F.; Stanton, C.; Hill, C.; et al. The influence of rosuvastatin on the gastrointestinal microbiota and host gene expression profiles. Am. J. Physiol. Gastrointest. Liver Physiol. 2017, 312, G488–G497. [CrossRef]
45. Vieira-Silva, S.; Falony, G.; Belda, E.; Nielsen, T.; Aron-Wisnewsky, J.; Chakaroun, R.; Forslund, S.K.; Assmann, K.; Valles-Colomer, M.; Nguyen, T.T.D.; et al. Statin therapy is associated with lower prevalence of gut microbiota dysbiosis. Nature 2020, 581, 310–315. [CrossRef]
46. Dias, A.M.; Cordeiro, G.; Estevinho, M.M.; Veiga, R.; Figueira, L.; Reina-Couto, M.; Magro, F.; the Clinical Pharmacology Unit, South. Med. J. 2005, 98, 1423–1428. [CrossRef] [PubMed]
47. Siegelman, E.S.; Rosen, M.A. Imaging of hepatic steatosis. Int. J. Clin. Pract. 2001, 55, 125–133. [CrossRef]
48. Petrella, L.A.; Solub, S.P.; Cheknis, A.; Nagaro, K.; Kean, Y.; Sears, P.S.; Babakhani, F.; Johnson, S.; Gerdinger, D.N. Decreased cure and increased recurrence rates for Clostridium difficile infection caused by the epidemic C. difficile BI strain. Clin. Infect. Dis. 2012, 55, 351–357. [CrossRef]
49. Charlie, M.E.; Pompei, P.; Ales, K.L.; MacKenzie, C.R. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J. Chronic Dis. 1987, 40, 373–383. [CrossRef]
50. McDonald, L.C.; Gerdinger, D.N.; Johnson, S.; Bakken, J.S.; Carroll, K.C.; Coffin, S.E.; Dubberke, E.R.; Garey, K.W.; Gould, C.V.; Kelly, C.; et al. Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin. Infect. Dis. 2018, 66, e1–e48. [CrossRef] [PubMed]
51. Debast, S.B.; Bauer, M.P.; Kuiper, E.J.; European Society of Clinical, M.; Infectious, D. European Society of Clinical Microbiology and Infectious Diseases: Update of the treatment guidance document for Clostridium difficile infection. Clin. Microbiol. Infect. 2014, 20 (Suppl. 2), 1–26. [CrossRef] [PubMed]
52. Ooijevaar, R.E.; van Beurden, Y.H.; Terveer, E.M.; Goorhuis, A.; Bauer, M.P.; Keller, J.J.; Mulder, C.J.J.; Kuiper, E.J. Update of treatment algorithms for Clostridium difficile infection. Clin. Microbiol. Infect. 2018, 24, 452–462. [CrossRef] [PubMed]
55. Miller, M.A.; Louie, T.; Mullane, K.; Weiss, K.; Lentnek, A.; Golan, Y.; Kean, Y.; Sears, P. Derivation and validation of a simple clinical bedside score (ATLAS) for Clostridium difficile infection which predicts response to therapy. *BMC Infect. Dis.* **2013**, *13*, 148. [CrossRef]

56. Sterling, R.K.; Lissen, E.; Clumeck, N.; Sola, R.; Correa, M.C.; Montaner, J.; Sulkowski, M.S.; Torriani, F.J.; Dieterich, D.T.; Thomas, D.L.; et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. *Hepatology* **2006**, *43*, 1317–1325. [CrossRef]

57. Levey, A.S.; Stevens, L.A.; Schmid, C.H.; Zhang, Y.L.; Castro, A.F., 3rd; Feldman, H.I.; Kusek, J.W.; Eggers, P.; Van Lente, F.; Greene, T.; et al. A new equation to estimate glomerular filtration rate. *Ann. Intern. Med.* **2009**, *150*, 604–612. [CrossRef]

58. Papic, N.; Maric, L.S.; Vince, A. Efficacy of oral vancomycin in primary prevention of Clostridium Difficile infection in elderly patients treated with systemic antibiotic therapy. *Infect. Dis.* **2018**, *50*, 483–486. [CrossRef] [PubMed]

59. Van Hise, N.W.; Bryant, A.M.; Hennessey, E.K.; Crannage, A.J.; Khoury, J.A.; Manian, F.A. Efficacy of Oral Vancomycin in Preventing Recurrent Clostridium difficile Infection in Patients Treated With Systemic Antimicrobial Agents. *Clin. Infect. Dis* **2016**, *63*, 651–653. [CrossRef]